WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment. WHO. (2019)
 |
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
Keywords: TB, HIV, drug-resistant, treatment, support and care
|
Tuberculosis and HIV — Progress towards the 2020 Target. UNAIDS. (2019)
 |
Most countries are not on track and too many people living with HIV are still dying from TB which is preventable and curable. The most vulnerable and the marginalized are still out of reach of HIV and TB services and in around 40 countries the number of TB deaths among people living with HIV is increasing. This is unacceptable.
|
Multisectoral Accountability Framework to Accelerate Progress to End Tuberculosis by 2030. WHO. (2019)
 |
In November 2017, 117 national delegations adopted the Moscow Declaration to End TB at the first WHO Global Ministerial Conference on Ending TB: A Multisectoral Response. They committed to “supporting the development of a multisectoral accountability framework” to accelerate progress to end TB. They called on WHO to develop the framework, working in close cooperation with relevant partners. At the 71st World Health Assembly (WHA) in May 2018, Member States welcomed the WHO draft multisectoral accountability framework (hereafter referred to as the MAF-TB). The WHA also requested the Director-General to continue to develop the MAF-TB, in consultation with Member States, and working in close collaboration with partners, as well as to provide technical support for national adaptation and use of the MAF-TB.
Keywords: SDG, TB, development, funding, monitoring and reporting
|
Tuberculosis and HIV. UNAIDS. (2019)
 |
TB is the leading cause of death among people living with HIV.
|
Timeline of HIV and TB. UNAIDS. (2019)
 |
Tuberculosis is the leading cause of illness and death among people living with HIV. TB can be cured.
Keywords: HIV, TB, PLHIV, treatment
|
Multi-Country Western Pacific Integrated HIV/TB Programme: Annual Results Report 2018. UNDP Pacific. (2019)
 |
This was the first year of the new funding cycle for the Multi-Country Western Pacific Integrated HIV/tuberculosis (TB) Programme. The three-year (2018-2020) US$11,368,713 programme is supported by the Global Fund and aims to strengthen control of HIV and TB in 11 Pacific island countries: Cook Islands, Federated States of Micronesia, Kiribati, Nauru, Niue, Palau, Republic of Marshall Islands, Samoa, Tonga, Tuvalu and Vanuatu. The United Nations Development Programme is the programme’s Principal Recipient.
|
FOCUS ON: Drug-resistant Tuberculosis. The Global Fund. (2019)
 |
Drug-resistant TB is part of the growing challenge of antimicrobial-resistant superbugs that do not respond to existing medications, resulting in fewer treatment options and increasing mortality rates for illnesses that would ordinarily be curable – including TB. Global development partners must move faster to contain this threat of antimicrobial resistance (AMR) before it escalates to claim millions of lives around the world.
|
Global Tuberculosis Report 2019. WHO. (2019)
 |
TB remains one of the top 10 causes of death worldwide. Millions of people continue to fall sick from TB each year. The Global TB Report 2019 provides a comprehensive and up-to-date assessment of the TB epidemic, and progress in the response, at global, regional and country levels. It features data on disease trends and the response to the epidemic in 202 countries and territories.
The Global Report includes trends in TB incidence and mortality, data on case detection and treatment results for TB, multidrug-resistant TB (MDR-TB), TB/HIV, TB prevention, universal health coverage as well as financing. It presents progress towards targets set at the first-ever United Nations General Assembly high-level meeting on TB in 2018, that brought together heads of state, as well as the targets of the WHO End TB Strategy and the Sustainable Development Goals.
The report also includes an overview of pipelines for new TB diagnostics, drugs and vaccines. Additionally, it outlines a monitoring framework that features data on SDG indicators that can be used to identify key influences on the TB epidemic at national level and inform the multi-sectoral actions required to end the TB epidemic.
- Country Profiles for 30 High TB Burden Countries
|
People-centred Framework for Tuberculosis Programme Planning and Prioritization - User Guide. WHO. (2019)
 |
The aim of the people-centred framework is to help countries to develop fully prioritized and budgeted NSPs based on a culture of making full use of the available data, which are aligned with national planning cycles and which provide the basis for a robust national response that can accelerate progress towards the goal of ending TB. In addition, applying the framework for other possible applications according to the country’s planning and policy cycle encourages the culture of data utilization and evidence translation into decision making and planning.
|
Annual Report 2017. SAARC Tuberculosis and HIV/AIDS Centre (STAC). (2019)
 |
The Annual Report of SAARC TB and HIV/AIDS Centre (STAC) is being presented indicating the programmes, activities and achievements of the year 2017. This is the Twenty-second consecutive comprehensive Annual Report STAC. This report includes a summary of the activities carried out by the Centre for the year 2017 along with introduction, goals, objectives, vision, mission and achievements of the Centre.
|
Pages
